Healthcare Innovation

Proteomic Age Gap May Predict MS Progression Early

A proteomic age gap may predict MS progression early, offering potential for early detection and monitoring of multiple sclerosis.

Proteomic Age Gap May Predict MS Progression Early

A gap between proteomic age and chronological age may help predict MS progression and symptom severity, according to research presented at the American Neurological Association’s 151st annual meeting. This gap, observed before and after symptom onset, suggests potential for early detection and monitoring of multiple sclerosis.

The findings suggest that this age gap could enable early detection of multiple sclerosis in high-risk populations, said Fatemeh Siavoshi, MD, a neurology postdoctoral research fellow at Johns Hopkins University School of Medicine. Siavoshi emphasized that this could influence monitoring frequency and treatment aggressiveness for patients.

Biological age vs. chronological age in MS

While chronological age is a known factor in MS behavior, individuals of the same age can experience the disease differently. Biological age, which reflects molecular and cellular changes, varies significantly among people of the same chronological age and is predictive of disease and mortality. Biological age is measured using aging clocks, such as proteomics, trained on blood samples to recognize aging patterns.

Researchers used aging clocks based on proteomics to measure biological age. They analyzed 134 individuals with MS (mean age = 27.8; 30% female) and 79 healthy controls (mean age = 27.3; 29% female) from the Department of Defense Serum Repository Cohort, along with 348 MS patients (mean age = 51.6; 71% female) and 49 controls from a Johns Hopkins University cohort. The DoD cohort included 170 presymptomatic samples collected over a median of 4 years and 98 post-onset samples, while the Hopkins cohort had a median disease duration of 12 years.

Age gaps and MS severity

The study found that people with MS had a larger systemic age gap compared to controls. In the Hopkins cohort, the gap was 2.2 years larger on average (P = 8.6e-06), while in the DoD cohort, it was 1 year larger before symptom onset (P = .002) and 0.7 years larger after onset (P = .04). These gaps were analyzed in relation to disability scores, MRI imaging, and optical coherence tomography.

Organ-specific age gaps also varied. In the Hopkins cohort, gaps were larger for muscle (2.5 years), immune system (1.8 years, P = .003), and brain (1.7 years). The DoD cohort showed a 2.4-year larger brain age gap (P < .001) and a 2-year larger liver age gap in presymptomatic patients. Post-onset, the brain age gap increased to 3.2 years.

Interestingly, no immune age acceleration was observed before or immediately after MS onset, despite MS being an immune-mediated disease. Siavoshi noted this as surprising, suggesting immunosenescence may develop with disease duration rather than triggering MS.

A higher systemic age gap was linked to greater disability scores and slower walking speed. Similarly, a larger muscle age gap correlated with worse manual dexterity and slower walking. The brain age gap, however, did not significantly correlate with disability scores.

The proteomic age gap could serve as a measurable target in clinical trials, potentially identifying causal protein pathways for targeted therapies. Siavoshi highlighted the need to test how these gaps change over time and predict progression beyond traditional measures like age and MRI.

Proteomic Age Gap and Clinical Outcomes

Researchers analyzed the relationship between proteomic age gaps and clinical outcomes in MS patients. These findings show the potential of proteomic age gaps as biomarkers for MS progression.

Future Directions and Clinical Applications

The study’s findings have significant implications for MS management and treatment. By identifying proteomic age gaps as a potential biomarker, clinicians may be able to detect MS earlier in high-risk populations and monitor disease progression more effectively. Siavoshi presented these findings at the American Neurological Association Conference in San Diego, October 17-20, 2026, emphasizing the gaps’ complementary role in tracking structural damage and functional disability.

Leave a Reply

Your email address will not be published. Required fields are marked *